Researchers at Georgia State University have developed an experimental antiviral pill that shows promise in preventing the spread of a measles-like virus. This drug, called GHP-88310, was effective in stopping transmission through both close contact and airborne routes in ferrets. It not only prevented the virus from spreading when administered shortly before or after exposure but also reduced the severity of symptoms in infected animals. These findings suggest that GHP-88310 could be a valuable tool in managing measles outbreaks alongside traditional vaccination methods.

This discovery is particularly relevant as measles outbreaks have reemerged across North America, resulting in thousands of infections and several deaths since 2025. For people concerned about their health and the health of their communities, the ability to quickly contain such outbreaks could significantly reduce the risk of severe illness and the social and economic burdens associated with prolonged quarantines. If GHP-88310 proves effective in humans, it could complement vaccination efforts and help manage future outbreaks more effectively.

The research is still in the early stages, having been tested in a controlled setting with ferrets. While the results are promising, they have not yet been proven in human trials. The researchers are preparing GHP-88310 for formal clinical testing, which will be crucial to determine its safety and efficacy in humans. Until then, it remains an exciting development in the fight against viral diseases like measles.

Source: Georgia State University